Literature DB >> 25032208

Disseminated infection due to Mycobacterium bovis after intravesical BCG instillation.

Sara Marquez-Batalla1, Esther Fraile-Villarejo1, Moncef Belhassen-García1, Nieves Gutierrez-Zubiaurre1, Miguel Cordero-Sánchez1.   

Abstract

Intravesical bacillus Calmette-Guerin (BCG) instillation has been adopted for the treatment of patients with superficial bladder cancer. Severe adverse events due to local instillation of BCG are uncommon, with an overall rate of serious complications of less than 5%. We report the case of an immunocompetent adult patient with multi-system effects, namely pneumonitis, granulomatous hepatitis and meningitis, who responded well to standard treatment for Mycobacterium bovis. This case highlights the importance of a thorough assessment of this type of patient.

Entities:  

Keywords:  Bacillus Calmette-Guerin; Bladder cancer; Mycobacterium bovis; Tuberculosis

Year:  2014        PMID： 25032208      PMCID： PMC4097160          DOI： 10.12998/wjcc.v2.i7.301

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN： 2307-8960            Impact factor:   1.337


  8 in total

Review 1.  Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.

Authors:  M Elkabani; J N Greene; A L Vincent; S VanHook; R L Sandin
Journal:  Cancer Control       Date:  2000 Sep-Oct       Impact factor: 3.302

2.  Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.

Authors:  Omar Y Gonzalez; Daniel M Musher; Indira Brar; Seth Furgeson; Maha R Boktour; Edward J Septimus; Richard J Hamill; Edward A Graviss
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

Review 3.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 4.  [Acute reactive arthritis after intravesical instillation of bacillus Calmette-Guérin. Two case reports and literature review].

Authors:  S Miranda; M Verdet; M Vernet; F Héron; O Vittecoq; H Levesque; I Marie
Journal:  Rev Med Interne       Date:  2010-05-21       Impact factor: 0.728

5.  Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

Authors:  Rocco Damiano; Marco De Sio; Giuseppe Quarto; Giuseppe Di Lorenzo; Sisto Perdonà; Italo M Palumbo; Giuseppina Azzarito; Francesco Giugliano; Riccardo Autorino
Journal:  BJU Int       Date:  2009-03-06       Impact factor: 5.588

6.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

7.  Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma.

Authors:  Krisztina A Nadasy; Rikin S Patel; Michael Emmett; Ricardo A Murillo; Marc A Tribble; Robert D Black; William L Sutker
Journal:  South Med J       Date:  2008-01       Impact factor: 0.954

8.  Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy.

Authors:  C McParland; D J Cotton; K S Gowda; V H Hoeppner; W T Martin; P F Weckworth
Journal:  Am Rev Respir Dis       Date:  1992-11
  8 in total
  3 in total

1.  Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette-Guérin for Treatment of Bladder Cancer.

Authors:  Elsa Alves Branco; Raquel Duro; Teresa Brito; António Sarmento
Journal:  Infect Dis Rep       Date:  2021-07-01

Review 2.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23

Review 3.  100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19.

Authors:  Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat
Journal:  Nat Rev Urol       Date:  2021-06-15       Impact factor: 14.432
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.